Organization
Tokyo Metropolitan Cancer and Infectious Diseases Center
3 abstracts
Abstract
Benefit of perioperative chemotherapy in the patients with loco-regional recurrence of HR-positive HER2-negative breast cancer: A multi-institutional retrospective cohort study.Org: Breast Medical Oncology Department, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Fukushima Medical University, School of Medicine, Department of Breast Oncology, Cancer Hospital of Xinjiang Medical University, Urumuqi, China, Research Institute for Radiation Biology and Medicine,
Abstract
Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in adults aged older than 75 years.Org: Kansai Medical University Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, National Cancer Center Hospital East, Kashiwa, Japan, Kitasato Daigaku Igakubu, Sagamihara-Shi Minami-Ku, Japan,
Abstract
A study on oligo-progression after durvalumab plus platinum-etoposide for ES-SCLC.Org: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan,